PL2371385T3 - Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń - Google Patents

Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń

Info

Publication number: PL2371385T3
Authority: PL; Poland
Prior art keywords: pigs; reduction; immunogenic composition; clinical signs; signs
Prior art date: 2005-12-29

Application number

PL11164854T

Other languages

English (en)

Inventor

Michael B Roof

Marc Allan Eichmeyer

Greg Nitzel

Phillip Wayne Hayes

Merrill Lynn Schaeffer

Original Assignee

Boehringer Ingelheim Vetmedica Inc

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2005-12-29

Filing date

2006-12-28

Publication date

2016-02-29

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38371964&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=PL2371385(T3) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2006-12-28 Application filed by Boehringer Ingelheim Vetmedica Inc filed Critical Boehringer Ingelheim Vetmedica Inc

2016-02-29 Publication of PL2371385T3 publication Critical patent/PL2371385T3/pl

Links

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/12—Viral antigens
- A61K39/125—Picornaviridae, e.g. calicivirus
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5252—Virus inactivated (killed)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5256—Virus expressing foreign proteins
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/525—Virus
- A61K2039/5258—Virus-like particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/55—Medicinal preparations containing antigens or antibodies characterised by the host/recipient, e.g. newborn with maternal antibodies
- A61K2039/552—Veterinary vaccine
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55516—Proteins; Peptides
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10022—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10023—Virus like particles [VLP]
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10034—Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10051—Methods of production or purification of viral material
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/10011—Circoviridae
- C12N2750/10071—Demonstrated in vivo effect
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
- C12N2750/00011—Details
- C12N2750/14011—Parvoviridae
- C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
- C12N2750/14141—Use of virus, viral particle or viral elements as a vector
- C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

Health & Medical Sciences (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Organic Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Virology (AREA)
Immunology (AREA)
Microbiology (AREA)
Epidemiology (AREA)
Mycology (AREA)
Genetics & Genomics (AREA)
Wood Science & Technology (AREA)
Zoology (AREA)
Biotechnology (AREA)
Oncology (AREA)
Communicable Diseases (AREA)
General Engineering & Computer Science (AREA)
Biochemistry (AREA)
Biomedical Technology (AREA)
Endocrinology (AREA)
Molecular Biology (AREA)
Diabetes (AREA)
Dermatology (AREA)
Hematology (AREA)
Reproductive Health (AREA)
Urology & Nephrology (AREA)
Pulmonology (AREA)
Gastroenterology & Hepatology (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Peptides Or Proteins (AREA)

PL11164854T 2005-12-29 2006-12-28 Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń PL2371385T3 (pl)

Applications Claiming Priority (4)

Application Number	Priority Date	Filing Date	Title
US75501605P	2005-12-29	2005-12-29
US82980906P	2006-10-17	2006-10-17
EP06850366.3A EP1976558B1 (en)	2005-12-29	2006-12-28	Pcv2 immunogenic composition for lessening clinical symptoms in pigs
EP11164854.9A EP2371385B1 (en)	2005-12-29	2006-12-28	Use of a PCV2 immunogenic composition for lessening clinical symptoms in pigs

Publications (1)

Publication Number	Publication Date
PL2371385T3 true PL2371385T3 (pl)	2016-02-29

Family

ID=38371964

Family Applications (4)

Application Number	Title	Priority Date	Filing Date
PL11164850T PL2371383T3 (pl)	2005-12-29	2006-12-28	Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń
PL11164854T PL2371385T3 (pl)	2005-12-29	2006-12-28	Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń
PL11164849T PL2371382T3 (pl)	2005-12-29	2006-12-28	Zastosowanie kompozycji immunogennej PCV2 do zmniejszania objawów klinicznych u świń
PL16185663T PL3127551T3 (pl)	2005-12-29	2006-12-28	Kompozycja immunogenna pcv2 do zmniejszania objawów klinicznych u świń

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
PL11164850T PL2371383T3 (pl)	2005-12-29	2006-12-28	Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń

Family Applications After (2)

Application Number	Title	Priority Date	Filing Date
PL11164849T PL2371382T3 (pl)	2005-12-29	2006-12-28	Zastosowanie kompozycji immunogennej PCV2 do zmniejszania objawów klinicznych u świń
PL16185663T PL3127551T3 (pl)	2005-12-29	2006-12-28	Kompozycja immunogenna pcv2 do zmniejszania objawów klinicznych u świń

Country Status (19)

Country	Link
US (12)	US20080181910A1 (pl)
EP (11)	EP3127551B1 (pl)
JP (2)	JP5739602B2 (pl)
KR (2)	KR20140019479A (pl)
CN (4)	CN104383526B (pl)
AR (1)	AR058871A1 (pl)
AU (1)	AU2006338182B2 (pl)
BR (1)	BRPI0620823B1 (pl)
CA (1)	CA2635430A1 (pl)
DK (6)	DK1976558T3 (pl)
ES (5)	ES2553253T3 (pl)
FI (1)	FI3766518T3 (pl)
HU (4)	HUE025994T2 (pl)
MX (4)	MX338626B (pl)
PL (4)	PL2371383T3 (pl)
PT (3)	PT2371383E (pl)
SG (1)	SG170792A1 (pl)
TW (1)	TW200800256A (pl)
WO (1)	WO2007094893A2 (pl)

Families Citing this family (48)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
FR2772047B1 (fr) *	1997-12-05	2004-04-09	Ct Nat D Etudes Veterinaires E	Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
US7833707B2 (en)	2004-12-30	2010-11-16	Boehringer Ingelheim Vetmedica, Inc.	Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7700285B1 (en)	2005-12-29	2010-04-20	Boehringer Ingelheim Vetmedica, Inc.	PCV2 immunogenic compositions and methods of producing such compositions
UA95602C2 (ru)	2004-12-30	2011-08-25	Берингер Ингельхейм Ветмедика, Инк.	Иммуногенная композиция цвс2 и способы приготовления такой композиции
US8834891B2 (en)	2005-03-14	2014-09-16	Boehringer Ingelheim Vetmedica, Inc.	Immunogenic compositions comprising Lawsonia intracellularis
EP1968630B1 (en)	2005-12-29	2018-01-24	Boehringer Ingelheim Vetmedica, Inc.	Multivalent pcv2 immunogenic compositions
MX338626B (es)	2005-12-29	2016-04-26	Boehringer Ingelheim Vetmed	Uso de una composicion inmunogenica de pcv2 para producir los sintomas clinicos en cerdos.
EP2099927A4 (en) *	2006-11-22	2010-05-05	Boehringer Ingelheim Vetmed	Methods of reducing porcine circovirus-associated disease outbreaks
EP2859900A1 (en) *	2006-12-11	2015-04-15	Boehringer Ingelheim Vetmedica, Inc.	Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
JP5200223B2 (ja) *	2006-12-15	2013-06-05	ベーリンガーインゲルハイムフェトメディカインコーポレイテッド	Ｐｃｖ２抗原によるブタの処置
EP1941903A1 (en) *	2007-01-03	2008-07-09	Boehringer Ingelheim Vetmedica Gmbh	Prophylaxis and treatment of PRDC
EP1958644A1 (en)	2007-02-13	2008-08-20	Boehringer Ingelheim Vetmedica Gmbh	Prevention and treatment of sub-clinical pcvd
US7829274B2 (en)	2007-09-04	2010-11-09	Boehringer Ingelheim Vetmedica, Inc.	Reduction of concomitant infections in pigs by the use of PCV2 antigen
CA2710247C (en) *	2007-12-21	2014-02-18	Wyeth Llc	Methods and compositions for immunizing pigs against porcine circovirus
WO2009088950A2 (en) *	2007-12-31	2009-07-16	Boehringer Ingelheim Vetmedica, Inc.	Pcv2 orf2 virus like particle with foreign amino acid insertion
KR20100113582A (ko) *	2008-01-23	2010-10-21	베링거잉겔하임베트메디카인코퍼레이티드	Ｐｃｖ2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법
US20110033495A1 (en) *	2008-02-15	2011-02-10	Boehringer Ingelheim Vetmedica, Inc.	Methods and compositions for reducing the impact of enteric diseases
TWI449533B (zh)	2008-04-18	2014-08-21	Intervet Int Bv	防備胞內勞森菌（Ｌａｗｓｏｎｉａｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）、豬肺炎黴漿菌（Ｍｙｃｏｐｌａｓｍａｈｙｏｐｎｅｕｍｏｎｉａｅ）及豬環狀病毒（Ｐｏｒｃｉｎｅｃｉｒｃｏｖｉｒｕｓ）用疫苗
AR078253A1 (es) *	2009-09-02	2011-10-26	Boehringer Ingelheim Vetmed	Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
CA2804604C (en)	2010-07-08	2023-10-03	United Biomedical, Inc.	Designer peptide-based pcv2 vaccine
TWI442935B (zh)	2010-12-22	2014-07-01	Sbc Virbac Ltd	豬第二型環狀病毒（ＰｏｒｃｉｎｅＣｉｒｃｏｖｉｒｕｓＴｙｐｅ２）、含彼之免疫組合物、檢測套組及其應用
UA114503C2 (uk)	2012-04-04	2017-06-26	Зоетіс Сервісіз Ллс	Комбінована вакцина pcv та mycoplasma hyopneumoniae
EP3049106A1 (en)	2013-09-25	2016-08-03	Zoetis Services LLC	Pcv2b divergent vaccine composition and methods of use
US9505808B2 (en)	2013-10-02	2016-11-29	Boehringer Ingelheim Vetmedica, Inc.	PCV2 ORF2 protein variant and virus like particles composed thereof
JP6488304B2 (ja)	2013-12-03	2019-03-20	インターベットインターナショナルベー．フェー．	ローソニア・イントラセルラリス（ｌａｗｓｏｎｉａｉｎｔｒａｃｅｌｌｕｌａｒｉｓ）及びブタサーコウイルス（ｐｏｒｃｉｎｅｃｉｒｃｏｖｉｒｕｓ）２に対するワクチン
ES2771899T3 (es)	2013-12-03	2020-07-07	Intervet Int Bv	Vacuna contra circovirus porcino de tipo 2
WO2017200956A1 (en)	2016-05-16	2017-11-23	Elixir Medical Corporation	Uncaging stent
RU2744193C2 (ru) *	2015-10-16	2021-03-03	Канзас Стейт Юниверсити Рисерч Фаундейшн	Иммуногенные композиции для иммунизации свиней против цирковируса типа 3 и способы их получения и применения
DK3399040T3 (da) *	2015-12-28	2021-08-30	Agricultural Tech Res Inst	Fremgangsmåde til fremstilling af porcine circovirus type 2 capsid-protein og farmaceutisk sammensætning omfattende samme
EP3432920A1 (en) *	2016-03-23	2019-01-30	Intervet International B.V.	A vaccine for intradermal application against pcv2 and prrs virus infection
WO2017162727A1 (en)	2016-03-23	2017-09-28	Intervet International B.V.	A combination vaccine against pcv2 and prrs virus infection comprising albumin
CN108697782A (zh)	2016-03-23	2018-10-23	英特维特国际股份有限公司	针对pcv2病毒和猪肺炎支原体感染的组合疫苗
US11622872B2 (en)	2016-05-16	2023-04-11	Elixir Medical Corporation	Uncaging stent
PT3534939T (pt)	2016-11-03	2023-04-20	Boehringer Ingelheim Vetmedica Gmbh	Vacina contra parvovírus porcino e vírus da síndrome reprodutiva e respiratória porcina e métodos da sua produção
US11311614B2 (en)	2017-04-13	2022-04-26	Intervet Inc.	Vaccines containing swine pathogens for associated non-mixed use
US12599490B2 (en)	2017-05-25	2026-04-14	Elixir Medical Corporation	Uncaging stent
CN109010818B (zh) *	2017-06-09	2021-11-09	普莱柯生物工程股份有限公司	一种预防和/或治疗猪圆环病毒感染的二联疫苗组合物及其制备方法和应用
WO2019025519A1 (en)	2017-08-03	2019-02-07	Intervet International B.V.	VACCINE COMPRISING GENOTYPE 2B PCV2 ORF2 PROTEIN
CN112773583B (zh)	2017-08-11	2024-01-09	万能医药公司	撑开支架
KR102665710B1 (ko)	2017-08-24	2024-05-14	노보 노르디스크 에이/에스	Glp-1 조성물 및 그 용도
CN119488586A (zh)	2018-03-26	2025-02-21	勃林格殷格翰动物保健美国有限公司	制备免疫原性组合物的方法
CN114222579A (zh)	2019-04-04	2022-03-22	勃林格殷格翰动物保健美国有限公司	猪圆环病毒3型（pcv3）疫苗及其生产和用途
US20220323567A1 (en)	2019-09-12	2022-10-13	Intervet Inc.	Combination vaccine for intradermal administration
JP7761567B2 (ja)	2020-02-18	2025-10-28	ノヴォノルディスクアー／エス	医薬製剤
FR3107454B1 (fr)	2020-02-20	2023-02-10	Soc Dexploitation De Produits Pour Les Industries Chimiques Seppic	Adjuvant de vaccin comprenant un microlatex inverse
CA3176154A1 (en)	2020-04-20	2021-10-28	Maarten Hendrik Witvliet	A combination of vaccines to prophylactically treat a pig
JP7657287B2 (ja)	2020-07-24	2025-04-04	ベーリンガーインゲルハイムアニマルヘルスユーエスエイインコーポレイテッド	組合せブタワクチン
WO2022090357A1 (en)	2020-10-29	2022-05-05	Intervet International B.V.	Combination vaccine for protecting swine against various disorders

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US755016A (en)	1903-06-08	1904-03-22	Charles Herschel Koyl	Coal-separating apparatus.
US829809A (en)	1906-04-10	1906-08-28	Arthur H Swan	Peel-blade tip.
US2909462A (en)	1955-12-08	1959-10-20	Bristol Myers Co	Acrylic acid polymer laxative compositions
US3479705A (en)	1966-12-15	1969-11-25	Miami Brick & Stone Inc Of Mia	Molding apparatus
NL7903764A (nl)	1979-05-14	1980-11-18	Shell Int Research	Werkwijze ter bereiding van calcium-houdend lood, daarmee verkregen lood en daaruit verkregen accuplaten of -roosters.
CA1247080A (en)	1983-03-08	1988-12-20	Commonwealth Serum Laboratories Commission	Antigenically active amino acid sequences
ES2052685T3 (es)	1987-03-17	1994-07-16	Akzo Nv	Metodo para producir un adyuvante libre.
US5069901A (en)	1988-02-03	1991-12-03	Jones Elaine V	Preparation of a recombinant subunit vaccine against pseudorabies infection
DE69027112T2 (de)	1989-01-23	1997-01-09	Auspharm International Ltd 4Th	Impfstoffzusammensetzung
US5155037A (en)	1989-08-04	1992-10-13	The Texas A&M University System	Insect signal sequences useful to improve the efficiency of processing and secretion of foreign genes in insect systems
US5202430A (en) *	1990-01-16	1993-04-13	University Of Tennessee	Transmissible gastroenteritis virus genes
CA2082155C (en)	1990-05-29	2008-04-15	Krishnaswamy I. Dayalu	Swine pneumonia vaccine and method of preparation
JP3046332B2 (ja) *	1990-08-02	2000-05-29	協和醗酵工業株式会社	発酵法によるアミノ酸の製造法
US5565205A (en) *	1990-08-16	1996-10-15	Solvay Animal Health, Inc.	Inactivated Mycoplasma hypopneumoniae bacterin and method of use thereof
NL9301272A (nl)	1993-07-20	1995-02-16	Aesculaap Bv	Chicken Anemia Virus mutanten en vaccins en toepassingen gebaseerd op de virale eiwitten VP1, VP2 en VP3 of daarvoor coderende sequenties van dat virus.
GB9023111D0 (en) *	1990-10-24	1990-12-05	Wellcome Found	Expression system
CA2094515C (en) *	1990-11-01	1998-09-01	Theodore T. Kramer	Bacterial attenuation method and vaccine
CA2076744C (en)	1991-08-26	2000-06-27	Danny W. Chladek	Viral agent associated with mystery swine disease
US6042830A (en)	1992-08-05	2000-03-28	Boehringer Ingelheim Vetmedica, Inc.	Viral agent associated with mystery swine disease
US5580557A (en)	1991-10-09	1996-12-03	Iowa State University Research Foundation, Inc.	Live, avirulent salmonella choleraesuis vaccine used for inducing an immune response in animals
US5338543A (en)	1992-02-27	1994-08-16	Ambico, Inc.	Thimerosal inactivated mycoplasma hyopneumoniae vaccine
CN1070078C (zh) *	1993-11-24	2001-08-29	中国农科院兰州兽医研究所	口蹄疫疫苗的生产工艺
PT759780E (pt)	1994-05-10	2001-01-31	American Home Prod	Vacina melhorada de vsrb vivo modificado
US5885823A (en) *	1995-06-05	1999-03-23	Nobl Laboratories, Inc.	Lawsonia intracellularis cultivation, anti-Lawsonia intracellularis vaccines and diagnostic agents
WO1998006835A2 (en)	1996-08-16	1998-02-19	The Texas A & M University System	Modifying insect cell gylcosylation pathways with baculovirus expression vectors
ATE199022T1 (de) *	1996-10-09	2001-02-15	Akzo Nobel Nv	Europäische vakzinstämme des fortplanzungs- atmungs-syndromsvirus des sweins (prrsv)
US6517843B1 (en) *	1999-08-31	2003-02-11	Merial	Reduction of porcine circovirus-2 viral load with inactivated PCV-2
FR2781159B1 (fr)	1998-07-06	2000-10-06	Merial Sas	Vaccin circovirus et parvovirus porcin
US20060029617A1 (en)	1997-10-03	2006-02-09	Charreyre Catherine E	Porcine circovirus and Helicobacter combination vaccines and methods of use
AU2002302120B2 (en) *	1997-10-03	2006-01-19	Merial	Porcine circoviruses, vaccines and diagnostic reagents
UA78180C2 (uk)	1997-10-03	2007-03-15	Меріаль	Кільцевий вірус свині типу ii, вакцини та діагностичні реагенти
US7211379B2 (en) *	1997-10-03	2007-05-01	Merial Sas	Prevention of myocarditis, abortion and intrauterine infection associated with porcine circovirus-2
US6391314B1 (en)	1997-10-03	2002-05-21	Merial	Porcine circoviruses vaccines diagnostic reagents
US7192594B2 (en) *	1997-10-03	2007-03-20	Merial Limited	Postweaning multisystemic wasting syndrome and porcine circovirus from pigs
US20040062775A1 (en) *	1997-12-05	2004-04-01	Agence Francaise De Securite Sanitaire Des Aliments	Circovirus sequences associated with piglet weight loss disease (PWD)
FR2772047B1 (fr) *	1997-12-05	2004-04-09	Ct Nat D Etudes Veterinaires E	Sequence genomique et polypeptides de circovirus associe a la maladie de l'amaigrissement du porcelet (map), applications au diagnostic et a la prevention et/ou au traitement de l'infection
JP3795751B2 (ja)	1997-12-11	2006-07-12	ユニバーシティオブサスカッチェワン	ブタからの離乳後多全身系消耗症候群ウイルス
EP1064024A4 (en)	1998-03-13	2005-04-06	Univ Georgia Res Found	VACCINES AGAINST CIRCOVIRUS INFECTIONS
US6294176B1 (en) *	1998-07-10	2001-09-25	Schering-Plough Veterinary Corp.	Recombinant raccoonpox virus and uses thereof as a vaccine in mammalian and avian species
DE19836659A1 (de)	1998-08-13	2000-02-17	Hoechst Schering Agrevo Gmbh	Herbizide Mittel für tolerante oder resistente Baumwollkulturen
DE69933647T2 (de)	1998-11-19	2007-08-23	Azwell Inc.	Rekombinante lysophosphatidsäure - phosphatase.
FR2789695B1 (fr)	1999-02-11	2003-03-07	Merial Sas	Vecteurs et vaccins viraux a base d'adenovirus porcins recombines et replicatifs
US6497883B1 (en)	1999-06-10	2002-12-24	Merial	Porcine circovirus recombinant poxvirus vaccine
US6943152B1 (en)	1999-06-10	2005-09-13	Merial	DNA vaccine-PCV
GB9921147D0 (en)	1999-09-07	1999-11-10	Smithkline Beecham Biolog	Novel composition
WO2001017556A1 (fr)	1999-09-07	2001-03-15	Shionogi & Co., Ltd.	Préparations vaccinales administrables par les muqueuses
GB9921146D0 (en)	1999-09-07	1999-11-10	Smithkline Beecham Biolog	Novel composition
US6656478B1 (en)	1999-11-12	2003-12-02	Samuel D. Charles	Cross-protective salmonella vaccines
ATE385808T1 (de)	1999-12-21	2008-03-15	Merial Sas	Mindestens ein cryptosporidium parvum-antigen und mindestens ein antigen eines anderen darmkrankheitserregers enthaltende zusammensetzungen und impfstoffe
US6808900B2 (en) *	2000-06-15	2004-10-26	Manitoba, University Of	Cryptosporidium parvum antigens, antibodies thereto and diagnostic and therapeutic compositions thereof
JP2004503234A (ja)	2000-06-15	2004-02-05	パーデュー・リサーチ・ファウンデーション	ブタの先天性振せん用ワクチン
US7018638B2 (en) *	2000-12-19	2006-03-28	Wyeth	Mycoplasma hyopneumoniae bacterin vaccine
MY129765A (en)	2000-12-19	2007-04-30	Wyeth Corp	Improved mycoplasma hyopneumoniae bacterin vaccine
JP2002247979A (ja)	2001-02-23	2002-09-03	Nippon Biologicals Inc	マレック病ワクチンおよびその製造方法
CN1309836C (zh) *	2001-03-27	2007-04-11	萨斯喀彻温大学	培养环状病毒的方法
US20030096377A1 (en)	2001-06-28	2003-05-22	Virginia Tech Intellectual Properties, Inc.	Differential PCR-RFLP assay for detecting and distinguishing between nonpathogenic PCV-1 and pathogenic PCV-2
WO2003003941A2 (en)	2001-07-02	2003-01-16	Pfizer Products Inc.	One dose vaccination with mycoplasma hyopneumoniae
US7361352B2 (en) *	2001-08-15	2008-04-22	Acambis, Inc.	Influenza immunogen and vaccine
US7279166B2 (en)	2001-12-12	2007-10-09	Virginia Tech Intellectual Properties, Inc.	Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US7276353B2 (en)	2001-12-12	2007-10-02	Virginia Tech Intellectual Properties, Inc.	Chimeric infectious DNA clones, chimeric porcine circoviruses and uses thereof
US6841364B2 (en) *	2002-01-22	2005-01-11	Protatek International, Inc.	Infectious cDNA clones of porcine reproductive and respiratory syndrome virus and expression vectors thereof
US20040121465A1 (en)	2002-02-14	2004-06-24	Novavax, Inc.	Optimization of gene sequences of virus-like particles for expression in insect cells
WO2003077860A2 (en)	2002-03-13	2003-09-25	Biophysica, Inc.	BOSWELLIN COMPOSITIONS ENHANCED WITH 3-β-ACETYL-11-KETO-β-BOSWELLIC ACID (“AKBA”), INDUSTRIAL MANUFACTURE AND THEIR USES
US20030215455A1 (en) *	2002-05-14	2003-11-20	Bailey Reynolds	Vaccine stabilizer and method of use
US7194472B2 (en) *	2002-07-05	2007-03-20	Sun Microsystems Inc.	Extending role scope in a directory server system
US7335362B2 (en) *	2002-07-19	2008-02-26	Beth Israel Deaconess Medical Center	Methods of treating pre-eclampsia or eclampsia
US7223207B1 (en) *	2002-09-13	2007-05-29	Simon Basyuk	Exercise and massage device
AU2002951692A0 (en)	2002-09-23	2002-10-17	Vital Biotech (Hong Kong) Limited	Improvements in or relating to vaccines
MXPA05008252A (es)	2003-02-03	2006-05-22	Cerebus Biolog Inc	Metodos para tratar, prevenir y detectar una infeccion con helicobacter.
US7563449B2 (en)	2003-04-21	2009-07-21	Pfizer Inc,	Methods for reducing cattle reproductive diseases
CN1458167A (zh)	2003-06-02	2003-11-26	中国农业科学院哈尔滨兽医研究所	截短表达的猪圆环病毒ⅱ型衣壳蛋白抗原及其应用
US7335361B2 (en) *	2003-06-09	2008-02-26	Animal Technology Institute Taiwan	Fusion antigen used as vaccine
NO321276B1 (no)	2003-07-07	2006-04-18	Elkem Materials	Fremgangsmate for fremstilling av triklorsilan og silisium for bruk ved fremstilling av triklorsilan
US7371395B2 (en) *	2003-07-24	2008-05-13	Merial Limited	Vaccine formulations
KR101131845B1 (ko) *	2003-07-25	2012-03-30	베링거잉겔하임베트메디카인코퍼레이티드	유럽 기원의 로소니아 인트라셀룰라리스, 및 이의 백신,진단제 및 사용 방법
FR2861731B1 (fr) *	2003-10-30	2006-02-24	Centre Nat Rech Scient	Nouvelle proteine de fixation du phosphate, compositions pharmaceutiques la contenant et ses utilisations
CN1942204A (zh)	2004-04-26	2007-04-04	株式会社中央疫苗研究所	用于猪呼吸病的灭活混合疫苗及其制备方法
CN1579553A (zh) *	2004-05-18	2005-02-16	浙江大学	Ii型猪圆环病毒核酸疫苗的制备方法及其应用
KR100478845B1 (ko)	2004-06-22	2005-03-24	채찬희	돼지 이유자돈 전신성 소모성 증후군 예방 및 치료용 생물학적 조성물
EP1778283A2 (en)	2004-06-30	2007-05-02	ID Biomedical Corporation of Quebec	Vaccine compositions for treating coronavirus infection
US7258075B1 (en) *	2004-08-13	2007-08-21	World Factory, Inc.	Collapsible bird feeder
UA95602C2 (ru)	2004-12-30	2011-08-25	Берингер Ингельхейм Ветмедика, Инк.	Иммуногенная композиция цвс2 и способы приготовления такой композиции
US7833707B2 (en)	2004-12-30	2010-11-16	Boehringer Ingelheim Vetmedica, Inc.	Methods of overexpression and recovery of porcine circovirus type 2 ORF2
US7700285B1 (en) *	2005-12-29	2010-04-20	Boehringer Ingelheim Vetmedica, Inc.	PCV2 immunogenic compositions and methods of producing such compositions
KR20070096019A (ko) *	2005-01-13	2007-10-01	베링거잉겔하임베트메디카게엠베하	향상된 ｐｒｒｓ 백신
US7300785B2 (en) *	2005-02-03	2007-11-27	Universiteit Ghent	Culturing circular ssDNA viruses for the production of vaccines
US8834891B2 (en)	2005-03-14	2014-09-16	Boehringer Ingelheim Vetmedica, Inc.	Immunogenic compositions comprising Lawsonia intracellularis
DK1869471T3 (en)	2005-04-13	2016-08-01	Merial Inc	PROCEDURE FOR MANUFACTURING PIG CIRCOVIRUS
US7691368B2 (en)	2005-04-15	2010-04-06	Merial Limited	Vaccine formulations
KR101347503B1 (ko) *	2005-09-09	2014-01-02	인터벳 인터내셔널 비.브이.	Ｐｃｖ-2 백신
EP1968630B1 (en)	2005-12-29	2018-01-24	Boehringer Ingelheim Vetmedica, Inc.	Multivalent pcv2 immunogenic compositions
MX338626B (es)	2005-12-29	2016-04-26	Boehringer Ingelheim Vetmed	Uso de una composicion inmunogenica de pcv2 para producir los sintomas clinicos en cerdos.
WO2007094983A2 (en)	2006-02-03	2007-08-23	Tanox, Inc.	Methods and compositions for the inhibition of hiv infection of t cells
EP2099927A4 (en)	2006-11-22	2010-05-05	Boehringer Ingelheim Vetmed	Methods of reducing porcine circovirus-associated disease outbreaks
EP2859900A1 (en)	2006-12-11	2015-04-15	Boehringer Ingelheim Vetmedica, Inc.	Effective method of treatment of porcine circovirus and lawsonia intracellularis infections
JP5200223B2 (ja)	2006-12-15	2013-06-05	ベーリンガーインゲルハイムフェトメディカインコーポレイテッド	Ｐｃｖ２抗原によるブタの処置
EP1941903A1 (en)	2007-01-03	2008-07-09	Boehringer Ingelheim Vetmedica Gmbh	Prophylaxis and treatment of PRDC
EP1958644A1 (en)	2007-02-13	2008-08-20	Boehringer Ingelheim Vetmedica Gmbh	Prevention and treatment of sub-clinical pcvd
GB0712160D0 (en)	2007-06-22	2007-08-01	Univ Ghent	Methods and compositions in the treatment of procine circoviral infection
US20090017064A1 (en) *	2007-07-10	2009-01-15	Wyeth	Methods and Compositions for Immunizing Pigs Against Porcine Circovirus
US7829274B2 (en)	2007-09-04	2010-11-09	Boehringer Ingelheim Vetmedica, Inc.	Reduction of concomitant infections in pigs by the use of PCV2 antigen
KR20100113582A (ko)	2008-01-23	2010-10-21	베링거잉겔하임베트메디카인코퍼레이티드	Ｐｃｖ2 마이코플라즈마 히오뉴모니에 면역원성 조성물 및 당해 조성물의 생산 방법
US20110033495A1 (en)	2008-02-15	2011-02-10	Boehringer Ingelheim Vetmedica, Inc.	Methods and compositions for reducing the impact of enteric diseases
US8444989B1 (en)	2008-04-18	2013-05-21	Boehringer Ingelheim Vetmedica Gmbh	One dose vaccination against mycoplasma infections of pigs
US20100150959A1 (en)	2008-12-15	2010-06-17	Vectogen Pty Ltd.	PCV 2-Based Methods and Compositions for the Treatment of Pigs
AR078253A1 (es)	2009-09-02	2011-10-26	Boehringer Ingelheim Vetmed	Metodos para reducir la actividad antivirica en composiciones pcv-2 y composiciones pcv-2 con mejor inmunogenicidad
WO2011075379A1 (en)	2009-12-18	2011-06-23	Boehringer Ingelheim Vetmedica, Inc.	Multivalent vaccine against porcine teschovirus and other disease causing organisms in swine
EP2547770B1 (en)	2010-03-16	2019-11-27	Virginia Tech Intellectual Properties, Inc.	Live attenuated chimeric porcine circovirus vaccine
US9580474B2 (en)	2010-09-08	2017-02-28	The Johns Hopkins University	Polyionic papilloma virus-like particle (VLP) vaccines
CN103122352B (zh)	2012-09-27	2015-02-11	华中农业大学	一种猪圆环病毒2型重组杆状病毒及制备方法和应用
EP2961766B1 (en)	2013-03-01	2019-04-10	Boehringer Ingelheim Vetmedica, Inc.	Quantification of vaccine compositions
US20140322267A1 (en)	2013-04-30	2014-10-30	Boehringer Ingelheim Vetmedica, Inc.	Orf2 protein of pcv2 subtype a (pcv2a) for use in cross-protection
WO2014187822A1 (en)	2013-05-22	2014-11-27	Boehringer Ingelheim Espana, S.A.	Method for the reduction of pcv-2 in a herd of swine
DK3035958T3 (en)	2013-08-23	2022-12-12	Boehringer Ingelheim Animal Health Usa Inc	Svine-circovirus type 2 (pcv2) subunit-vaccine
US9505808B2 (en)	2013-10-02	2016-11-29	Boehringer Ingelheim Vetmedica, Inc.	PCV2 ORF2 protein variant and virus like particles composed thereof
IL247927B (en)	2014-05-07	2022-09-01	Boehringer Ingelheim Int	Container, a device that turns a liquid into a fine spray and use
US10555994B2 (en)	2015-03-30	2020-02-11	Boehringer Ingelheim Animal Health USA Inc.	PCV2 ORF2 carrier platform

2006
- 2006-12-28 MX MX2013012700A patent/MX338626B/es unknown
- 2006-12-28 DK DK06850366.3T patent/DK1976558T3/en active
- 2006-12-28 ES ES11164850.7T patent/ES2553253T3/es active Active
- 2006-12-28 FI FIEP20184598.9T patent/FI3766518T3/fi active
- 2006-12-28 ES ES06850366.3T patent/ES2625903T3/es active Active
- 2006-12-28 WO PCT/US2006/062662 patent/WO2007094893A2/en not_active Ceased
- 2006-12-28 HU HUE11164854A patent/HUE025994T2/en unknown
- 2006-12-28 EP EP16185663.8A patent/EP3127551B1/en active Active
- 2006-12-28 EP EP11164858A patent/EP2371386A1/en not_active Withdrawn
- 2006-12-28 CN CN201410534903.8A patent/CN104383526B/zh active Active
- 2006-12-28 HU HUE16185663A patent/HUE051784T2/hu unknown
- 2006-12-28 KR KR1020147001544A patent/KR20140019479A/ko not_active Ceased
- 2006-12-28 HU HUE11164849A patent/HUE029552T2/en unknown
- 2006-12-28 SG SG201102211-8A patent/SG170792A1/en unknown
- 2006-12-28 DK DK20184598.9T patent/DK3766518T3/da active
- 2006-12-28 DK DK11164854.9T patent/DK2371385T3/en active
- 2006-12-28 AU AU2006338182A patent/AU2006338182B2/en active Active
- 2006-12-28 PL PL11164850T patent/PL2371383T3/pl unknown
- 2006-12-28 HU HUE11164850A patent/HUE026205T2/en unknown
- 2006-12-28 US US11/617,435 patent/US20080181910A1/en not_active Abandoned
- 2006-12-28 CA CA002635430A patent/CA2635430A1/en not_active Abandoned
- 2006-12-28 AR ARP060105837A patent/AR058871A1/es not_active Application Discontinuation
- 2006-12-28 DK DK16185663.8T patent/DK3127551T3/da active
- 2006-12-28 EP EP11164854.9A patent/EP2371385B1/en not_active Revoked
- 2006-12-28 KR KR1020087018597A patent/KR20080093112A/ko not_active Ceased
- 2006-12-28 EP EP20184598.9A patent/EP3766518B1/en active Active
- 2006-12-28 ES ES11164849.9T patent/ES2572736T3/es active Active
- 2006-12-28 EP EP11164849.9A patent/EP2371382B1/en not_active Revoked
- 2006-12-28 MX MX2012007937A patent/MX343001B/es unknown
- 2006-12-28 DK DK11164849.9T patent/DK2371382T3/en active
- 2006-12-28 EP EP10174456A patent/EP2275130A3/en not_active Withdrawn
- 2006-12-28 PL PL11164854T patent/PL2371385T3/pl unknown
- 2006-12-28 PT PT111648507T patent/PT2371383E/pt unknown
- 2006-12-28 PT PT111648549T patent/PT2371385E/pt unknown
- 2006-12-28 PT PT161856638T patent/PT3127551T/pt unknown
- 2006-12-28 EP EP11164850.7A patent/EP2371383B1/en not_active Revoked
- 2006-12-28 PL PL11164849T patent/PL2371382T3/pl unknown
- 2006-12-28 EP EP11164852A patent/EP2371384A1/en not_active Withdrawn
- 2006-12-28 EP EP06850366.3A patent/EP1976558B1/en not_active Revoked
- 2006-12-28 CN CN201811123454.2A patent/CN109125721A/zh active Pending
- 2006-12-28 EP EP11164855A patent/EP2374475A1/en not_active Withdrawn
- 2006-12-28 EP EP11164856A patent/EP2374476A1/en not_active Withdrawn
- 2006-12-28 BR BRPI0620823A patent/BRPI0620823B1/pt active IP Right Grant
- 2006-12-28 TW TW095149552A patent/TW200800256A/zh unknown
- 2006-12-28 MX MX2008008311A patent/MX2008008311A/es active IP Right Grant
- 2006-12-28 JP JP2008548847A patent/JP5739602B2/ja active Active
- 2006-12-28 ES ES16185663T patent/ES2824113T3/es active Active
- 2006-12-28 ES ES11164854.9T patent/ES2553254T3/es active Active
- 2006-12-28 MX MX2016013804A patent/MX356667B/es unknown
- 2006-12-28 CN CN201410534901.9A patent/CN104474541B/zh active Active
- 2006-12-28 CN CN200680053578.7A patent/CN101426522B/zh active Active
- 2006-12-28 DK DK11164850.7T patent/DK2371383T3/en active
- 2006-12-28 PL PL16185663T patent/PL3127551T3/pl unknown
2008
- 2008-06-11 US US12/136,942 patent/US7838213B2/en active Active
- 2008-06-11 US US12/137,067 patent/US7838214B2/en active Active
- 2008-06-11 US US12/136,923 patent/US7968285B2/en active Active
- 2008-06-11 US US12/137,105 patent/US20080279889A1/en not_active Abandoned
- 2008-06-11 US US12/137,141 patent/US7829273B2/en active Active
- 2008-06-11 US US12/137,086 patent/US20080267995A1/en not_active Abandoned
2011
- 2011-05-12 US US13/106,606 patent/US9011868B2/en active Active
2013
- 2013-01-04 JP JP2013000182A patent/JP2013067655A/ja active Pending
2015
- 2015-03-18 US US14/661,969 patent/US9669087B2/en active Active
2016
- 2016-03-21 US US15/076,381 patent/US9987349B2/en active Active
- 2016-08-26 US US15/249,158 patent/US9610345B2/en active Active
2018
- 2018-04-19 US US15/957,663 patent/US10568955B2/en active Active

Also Published As

Publication number	Publication date
KR20140019479A (ko)	2014-02-14
MX356667B (es)	2018-06-08
AU2006338182A1 (en)	2007-08-23
US9669087B2 (en)	2017-06-06
US7829273B2 (en)	2010-11-09
DK2371383T3 (en)	2015-11-30
EP2371382A1 (en)	2011-10-05
DK1976558T3 (en)	2017-06-19
EP3766518B1 (en)	2026-01-28
HUE026205T2 (en)	2016-05-30
HUE051784T2 (hu)	2021-03-29
TW200800256A (en)	2008-01-01
US20080279876A1 (en)	2008-11-13
BRPI0620823B1 (pt)	2017-02-21
US7838213B2 (en)	2010-11-23
ES2824113T3 (es)	2021-05-11
US20110217327A1 (en)	2011-09-08
US20080267995A1 (en)	2008-10-30
HUE029552T2 (en)	2017-03-28
CN104474541B (zh)	2019-08-23
WO2007094893A2 (en)	2007-08-23
WO2007094893A9 (en)	2016-09-09
US9610345B2 (en)	2017-04-04
DK2371385T3 (en)	2015-11-30
EP2275130A2 (en)	2011-01-19
US20170049875A1 (en)	2017-02-23
AU2006338182B2 (en)	2013-08-22
ES2553254T3 (es)	2015-12-07
EP2371385B1 (en)	2015-08-19
FI3766518T3 (fi)	2026-04-09
CN109125721A (zh)	2019-01-04
EP2275130A3 (en)	2011-03-23
MX343001B (es)	2016-10-21
DK3127551T3 (da)	2020-10-12
EP1976558A2 (en)	2008-10-08
KR20080093112A (ko)	2008-10-20
US20160193320A1 (en)	2016-07-07
CN104383526B (zh)	2018-09-18
EP2371386A1 (en)	2011-10-05
EP3127551B1 (en)	2020-07-29
US10568955B2 (en)	2020-02-25
EP3127551A1 (en)	2017-02-08
CN104474541A (zh)	2015-04-01
AR058871A1 (es)	2008-02-27
PT3127551T (pt)	2020-10-09
MX338626B (es)	2016-04-26
EP2371383B1 (en)	2015-08-19
EP2371384A1 (en)	2011-10-05
PL2371382T3 (pl)	2016-08-31
CN101426522A (zh)	2009-05-06
US20150190498A1 (en)	2015-07-09
EP1976558B1 (en)	2017-03-15
JP5739602B2 (ja)	2015-06-24
DK3766518T3 (da)	2026-04-13
BRPI0620823A2 (pt)	2011-11-22
US20180236057A1 (en)	2018-08-23
HUE025994T2 (en)	2016-05-30
ES2572736T3 (es)	2016-06-02
EP2374475A1 (en)	2011-10-12
EP2371382B1 (en)	2016-03-02
WO2007094893A3 (en)	2008-11-06
JP2013067655A (ja)	2013-04-18
EP2374476A1 (en)	2011-10-12
US9987349B2 (en)	2018-06-05
PT2371385E (pt)	2015-11-27
US20080261887A1 (en)	2008-10-23
EP2371385A1 (en)	2011-10-05
CA2635430A1 (en)	2007-08-23
PL3127551T3 (pl)	2020-12-28
US20080181910A1 (en)	2008-07-31
US20080260779A1 (en)	2008-10-23
ES2553253T3 (es)	2015-12-07
PL2371383T3 (pl)	2016-01-29
EP1976558A4 (en)	2009-04-29
US7968285B2 (en)	2011-06-28
JP2009522310A (ja)	2009-06-11
EP3766518A1 (en)	2021-01-20
ES2625903T3 (es)	2017-07-20
PT2371383E (pt)	2015-11-24
SG170792A1 (en)	2011-05-30
EP2371383A1 (en)	2011-10-05
DK2371382T3 (en)	2016-06-13
US20080279875A1 (en)	2008-11-13
CN104383526A (zh)	2015-03-04
US9011868B2 (en)	2015-04-21
US20080279889A1 (en)	2008-11-13
US7838214B2 (en)	2010-11-23
CN101426522B (zh)	2014-11-12
MX2008008311A (es)	2009-03-04

Publication	Publication Date	Title
PL2371385T3 (pl)	2016-02-29	Zastosowanie kompozycji immunogennej do zmniejszania objawów klinicznych u świń
FR22C1008I2 (fr)	2024-01-19	Composition immunogène
CY2018013I2 (el)	2018-09-05	Ανθρωπινα anti-il-23 αντισωματα, συνθεσεις, μεθοδοι και χρησεις
BRPI0716354A2 (pt)	2013-09-17	"composiÇço e mÉtodo"
PT1506781E (pt)	2005-07-29	Composicao para tratamento vaginal
CY2019042I1 (el)	2020-05-29	Οφθαλμολογικες συνθεσεις και η χρηση τους
EP2153838A4 (en)	2012-09-26	ANTI-NOROVIRUS AGENT AND COMPOSITION THEREOF
EP2327750A4 (en)	2011-12-07	LIABILITY AND LIABILITY THEREWITH
EP1962961A4 (en)	2010-12-01	HALF-BODY: THERAPEUTIC AGENTS ACTIVATED BY DIMÉRIZATION
IL191759A (en)	2015-05-31	Ganaxolone formulations and methods for the making and use thereof
ATE444748T1 (de)	2009-10-15	1-ä(3-hydroxy-adamant-1-ylamino)-acetylü- pyrrolidin-2(s)-carbonitril-formulierung mit modifizierter freisetzung
DK1827412T3 (da)	2014-02-10	Sammensætninger til anvendelse i kirurgi
PL2037902T3 (pl)	2013-12-31	Zastosowanie kanabidiolu w użyciu w leczeniu bólu neuropatycznego
IL190885A0 (en)	2008-11-03	Immunogenic compositions and methods of use
ZA200710858B (en)	2008-12-31	Diclofenac formulations and methods of use
EP2298365A4 (en)	2013-01-23	MEDICAL COMPOSITION AND MEDICAL KIT
DE602005008726D1 (de)	2008-09-18	Verwendet
SI1744756T1 (sl)	2008-10-31	Uporaba meloksikamskih formulacij v veterinarski medicini
EP1914273A4 (en)	2010-04-21	ETHER COMPOSITION AND SOLUTION COMPOSITION
FR2899234B1 (fr)	2017-02-17	Composition d'agent d'expansion
EP1977800A4 (en)	2010-05-26	CARD TOY
FI20041057L (fi)	2006-02-05	Pelkistysainekoostumus
EP2101736A4 (en)	2012-09-19	HOMOGENEOUS PULP AND GEL PREPARATIONS
FR2899233B1 (fr)	2010-03-12	Composition d'agent d'expansion
BRPI0719997A2 (pt)	2014-03-18	Uso de epotilonas no tratamento de osteoporose e doenças relacionadas